FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

André Scheen

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Procedures

Clinical Trials as Topic

Geographic Areas

Belgium

Co-author Network

Publications

TOP 3
Emmanuel Beck; André J Scheen
[Which anti-tumour benefits to be expected from metformin?].
André J Scheen
Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease.
André J Scheen
[In Process Citation].

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of André Scheen (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Emmanuel Beck; André J Scheen
[Which anti-tumour benefits to be expected from metformin?].
Annales d'endocrinologie 2013;74(2):137-47.
2013: André J Scheen
Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease.
Expert opinion on drug metabolism & toxicology 2013;9(5):529-50.
2013: André J Scheen
[In Process Citation].
Revue médicale de Liège 2013;68(3):154-5.
2013: J De Flines; N Esser; Françoise Luyckx; Nicolas Paquot; M Rorive; André J Scheen
[Clinical evaluation of an obese person].
Revue médicale de Liège 2013;68(3):148-53.
2013: André J Scheen
Efficacy and safety of Jentadueto® (linagliptin plus metformin).
Expert opinion on drug safety 2013;12(2):275-89.
2013: André J Scheen
Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation.
Expert opinion on drug metabolism & toxicology 2013;9(3):363-77.
2013: M Tyberghein; Jean-Marie Krzesinski; JC Philips; André J Scheen
[Orthostatic hypotension: definition, symptoms, assessment and pathophysiology].
Revue médicale de Liège 2013;68(2):65-73.
2013: André J Scheen
Cardiovascular effects of gliptins.
Nature reviews. Cardiology 2013;10(2):73-84.
2013: André J Scheen
[Limited add-on value of oral glucose-lowering agents in type 1 diabetes].
Revue médicale de Liège 2013;68(1):16-21.
2012: André J Scheen; C Mathieu
[Management of hyperglycaemia in type 2 diabetes: a patient-centered approach].
Revue médicale de Liège 2012;67(12):623-31.
2012: André J Scheen; P Ernest; BJ Jandrain
[How I explore ... a risk difference in the occurrence of an event in clinical trials].
Revue médicale de Liège 2012;67(11):597-602.
2012: André J Scheen
Outcomes and lessons from the PROactive study.
Diabetes research and clinical practice 2012;98(2):175-86.
2012: M Franck; Nicolas Paquot; André J Scheen
[Influence of body weight on the natural history of and the therapeutic approaches to type 1 diabetes].
Revue médicale de Liège 2012;67(9):461-7.
2012: J De Flines; A De Roover; M Franck; Nicolas Paquot; M Rorive; André J Scheen
[Metabolic surgery: an increasing place in the management of diabetes].
Revue médicale suisse 2012;8(351):1621-4, 1626-7.
2012: André J Scheen
[Use of oral glucose-lowering agents in patients with renal impairment].
Revue médicale suisse 2012;8(351):1614-20.
2012: André J Scheen; Nicolas Paquot
Gliptin versus a sulphonylurea as add-on to metformin.
Lancet 2012;380(9840):450-2.
2012: André J Scheen
Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes.
Expert opinion on drug metabolism & toxicology 2012;8(6):745-58.
2012: Claudine Piérard-Franchimont; Pascale Quatresooz; Gérald E Piérard; André J Scheen
[The psoriasis--metabolic syndrome comorbidity, a complex multigenic disease].
Revue médicale de Liège 2012;67(5-6):337-40.
2012: André J Scheen; Nicolas Paquot
[Type 2 diabetes: journey in the heart of a complex disease].
Revue médicale de Liège 2012;67(5-6):326-31.
2012: André J Scheen; D Giet
[Role of environment in complex diseases: air pollution and food contaminants].
Revue médicale de Liège 2012;67(5-6):226-33.
2012: André J Scheen
DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
Diabetes & metabolism 2012;38(2):89-101.
2012: André J Scheen; J-C Philips; Jean-Marie Krzesinski
[Hypertension and diabetes: about a common but complex association].
Revue médicale de Liège 2012;67(3):133-8.
2012: André J Scheen
Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment.
Expert opinion on drug metabolism & toxicology 2012;8(3):383-94.
2012: André J Scheen
Dipeptidylpeptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) receptor agonists: yes.
European journal of internal medicine 2012;23(2):126-31.
2012: Nicolas Paquot; André J Scheen
[Which HbA1c and lipid targets in patients with type 2 diabetes?].
Revue médicale de Liège 2012;67(2):98-103.
2012: André J Scheen; Luc F Van Gaal
[Linagliptin (Trajenta): a selective DPP-4 inhibitor with limited renal elimination].
Revue médicale de Liège 2012;67(2):91-7.
2012: Jean-Marie Krzesinski; André J Scheen
[Which blood pressure targets in patients with type 2 diabetes?].
Revue médicale de Liège 2012;67(1):51-6.
2011: André J Scheen
Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation).
Expert opinion on drug metabolism & toxicology 2011;7(12):1561-76.
2011: André J Scheen
[Alternative drugs to statins].
La Revue du praticien 2011;61(8):1121-2.
2011: André J Scheen
[Statins in the management of dyslipidemias].
La Revue du praticien 2011;61(8):1120-6.
2011: André J Scheen
Cytochrome P450-mediated cardiovascular drug interactions.
Expert opinion on drug metabolism & toxicology 2011;7(9):1065-82.
2011: André J Scheen; Régis P Radermecker; P Ernest; BJ Jandrain
[Renal SGLT2 inhibitors, new agents for the management of type 2 diabetes].
Revue médicale suisse 2011;7(306):1621-4, 1626-9.
2011: N Esser; Nicolas Paquot; André J Scheen
[Type 2 diabetes and anti-inflammatory agents: new therapeutic prospects?].
Revue médicale suisse 2011;7(306):1614-8, 1620.
2011: Jean-Christophe Philips; André J Scheen
Squatting test: A posture to study and counteract cardiovascular abnormalities associated with autonomic dysfunction.
Autonomic neuroscience : basic & clinical 2011;162(1-2):3-9.
2011: André J Scheen; Luc F Van Gaal
[Glycemic control before and after sitagliptin in general medical practice: analysis of determinant factors in the Belgian observational study "SUGAR"].
Revue médicale de Liège 2011;66(7-8):440-6.
2011: André J Scheen; E Beck; J De Flines; M Rorive
[Obesity, insulin resistance and type 2 diabetes: risk factors for breast cancer].
Revue médicale de Liège 2011;66(5-6):238-44.
2011: André J Scheen
Sibutramine on cardiovascular outcome.
Diabetes care 2011;34 Suppl 2():S114-9.
2011: André J Scheen; Nicolas Paquot
[Therapeutic approaches to improve blood glucose control in a patient with type 2 diabetes on a metformin-sulfonylurea combination].
Revue médicale de Liège 2011;66(4):215-21.
2011: André J Scheen; Ulysse J Gaspard
[Medication of the month. Femoston Low (0.5 mg estradiol plus 2.5 mg dydrogesterone) for menopausal hormonal replacement therapy].
Revue médicale de Liège 2011;66(4):209-14.
2011: André J Scheen; J De Flines; M Rorive; Arnaud De Roover; Nicolas Paquot
[Metabolic surgery: an evolution (or revolution) of bariatric surgery?].
Revue médicale de Liège 2011;66(4):183-90.
2011: André J Scheen; Nicolas Paquot
[Clinical vignette. Which combination of oral glucose-lowering agents to use after failure of metformin monotherapy in type 2 diabetes?].
Revue médicale de Liège 2011;66(3):170-5.
2011: André J Scheen; JC Philips; Jean-Marie Krzesinski
[Dizziness: hypoglycemia, hypotension or spasmophilia?].
Revue médicale de Liège 2011;66(1):48-54.
2010: André J Scheen
[Medication of the month. Sitagliptin-metformin fixed combination (Janumet)].
Revue médicale de Liège 2010;65(11):648-54.
2010: Régis P Radermecker; A Saint Remy; André J Scheen; J Bringer; E Renard
Continuous glucose monitoring reduces both hypoglycaemia and HbA1c in hypoglycaemia-prone type 1 diabetic patients treated with a portable pump.
Diabetes & metabolism 2010;36(5):409-13.
2010: Jean-Christophe Philips; Monique Marchand; André J Scheen
Pulsatile stress in middle-aged patients with type 1 or type 2 diabetes compared with nondiabetic control subjects.
Diabetes care 2010;33(11):2424-9.
2010: Régis P Radermecker; André J Scheen
Management of blood glucose in patients with stroke.
Diabetes & metabolism 2010;36 Suppl 3():S94-9.
2010: André J Scheen
Central nervous system: a conductor orchestrating metabolic regulations harmed by both hyperglycaemia and hypoglycaemia.
Diabetes & metabolism 2010;36 Suppl 3():S31-8.
2010: André J Scheen
[Suspension of the commercialization of sibutramine and rosiglitazone in Europe].
Revue médicale de Liège 2010;65(10):574-9.
2010: André J Scheen; Guillaume Charpentier; Carl Johan Ostgren; Asa Hellqvist; Ingrid Gause-Nilsson
Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus.
Diabetes/metabolism research and reviews 2010;26(7):540-9.
2010: André J Scheen
Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin.
Expert opinion on drug metabolism & toxicology 2010;6(10):1265-76.
2010: Pierre Delanaye; André J Scheen
Effects of fibrates on cardiovascular outcomes.
Lancet 2010;376(9746):1051; author reply 1051-2.
2010: André J Scheen; Luc F Van Gaal
[Clinical study of the month. Accord-lipid and accord-eye: towards a new positioning of fenofibrate in the management of type 2 diabetes].
Revue médicale de Liège 2010;65(9):533-9.
2010: André J Scheen
[Saxagliptin (Onglyza): new inhibitor of the dipeptidylpeptidase-4 for the oral treatment of type 2 diabetes].
Revue médicale de Liège 2010;65(9):527-32.
2010: Alessandra Iovino; Nicolas Paquot; André J Scheen
[Reduction of obesity-related metabolic risk by modulating tissue exposition to cortisol].
Revue médicale suisse 2010;6(260):1608-12.
2010: Emmanuel Beck; André J Scheen
[Anti-cancer activity of metformin: new perspectives for an old drug].
Revue médicale suisse 2010;6(260):1601-7.
2010: Vincianne Thielen; Régis P Radermecker; Eric Renard; Jacques Bringer; André J Scheen
[Therapeutic education and continuous glucose monitoring in insulin-treated diabetic patients].
Revue médicale suisse 2010;6(260):1596-600.
2010: André J Scheen; Nicolas Paquot
[Multirisk approach of the type 2 diabetic patient: controversies surrounding target values after the ACCORD trial].
Revue médicale suisse 2010;6(260):1582-7.
2010: André J Scheen
[Apathy and therapeutic non-observance].
Revue médicale suisse 2010;6(260):1571-2.
2010: André J Scheen
Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
Clinical pharmacokinetics 2010;49(9):573-88.
2010: André J Scheen
Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
Diabetes, obesity & metabolism 2010;12(8):648-58.
2010: André J Scheen
[A patient with cardiovascular risk factors and comorbidities: integration of indications and contra-indications in pharmacotherapy].
Revue médicale de Liège 2010;65(7-8):476-81.
2010: André J Scheen; Luc F Van Gaal
[Liraglutide (Victoza): human glucagon-like peptide-1 used in once daily injection for the treatment of type 2 diabetes].
Revue médicale de Liège 2010;65(7-8):464-70.
2010: JC Philips; M Marchand; André J Scheen
Changes in pulse pressure, heart rate and the pulse pressure x heart rate product during squatting in Type 1 diabetes according to age.
Diabetic medicine : a journal of the British Diabetic Association 2010;27(7):753-61.
2010: André J Scheen
Controversy about the cardiovascular safety of sibutramine.
Drug safety : an international journal of medical toxicology and drug experience 2010;33(7):615-8.
2010: A Pintiaux; N Chabbert-Buffet; JC Philips; André J Scheen; Jean-Michel Foidart
[Diabetes and pregnancy: impact of medical inertia and therapeutic compliance].
Revue médicale de Liège 2010;65(5-6):399-404.
2010: J C Philips; André J Scheen
[Clinical inertia in the management of patients with type 2 diabetes: how to solve it?].
Revue médicale de Liège 2010;65(5-6):318-25.
2010: Régis P Radermecker; André J Scheen
[How to optimize lipid-lowering therapy: do not forget patient's non-compliance].
Revue médicale de Liège 2010;65(5-6):311-7.
2010: André J Scheen; Pierre J Lefebvre; HE Kulbertus
[Cardiovascular prevention: could the polypill reduce the risk of clinical inertia and poor compliance?].
Revue médicale de Liège 2010;65(5-6):267-72.
2010: André J Scheen; J P Bourguignon; M Guillaume
[Therapeutic education: a solution to reduce therapeutic inertia and noncompliance].
Revue médicale de Liège 2010;65(5-6):250-5.
2010: BJ Jandrain; Ph Ernest; Régis P Radermecker; André J Scheen
[Strategies avoiding inertia and non compliance in clinical trials].
Revue médicale de Liège 2010;65(5-6):246-9.
2010: André J Scheen; Didier Giet
[Non compliance to medical therapy; causes, consequences, solutions].
Revue médicale de Liège 2010;65(5-6):239-45.
2010: André J Scheen
[Inertia in clinical practice: causes, consequences, solutions].
Revue médicale de Liège 2010;65(5-6):232-8.
2010: André J Scheen; Régis P Radermecker
Addition of incretin therapy to metformin in type 2 diabetes.
Lancet 2010;375(9724):1410-2.
2010: J De Flines; André J Scheen
Management of metabolic syndrome and associated cardiovascular risk factors.
Acta gastro-enterologica Belgica 2010;73(2):261-6.
2010: André J Scheen
[NAVIGATOR: A trial of prevention of cardiovascular complications and type 2 diabetes with valsartan and/or nateglinide].
Revue médicale de Liège 2010;65(4):217-23.
2010: N Esser; Nicolas Paquot; André J Scheen
[Fitness versus fatness: respective cardiometabolic impacts at different age ranges].
Revue médicale de Liège 2010;65(4):199-205.
2010: André J Scheen
Cardiovascular risk-benefit profile of sibutramine.
American journal of cardiovascular drugs : drugs, devices, and other interventions 2010;10(5):321-34.
2009: André J Scheen; J De Flines; A De Roover; Nicolas Paquot
Bariatric surgery in patients with type 2 diabetes: benefits, risks, indications and perspectives.
Diabetes & metabolism 2009;35(6 Pt 2):537-43.
2009: M Rorive; J De Flines; Nicolas Paquot; André J Scheen
[Management of an obese person with metabolic syndrome].
Revue médicale de Liège 2009;64(12):651-6.
2009: André J Scheen; Régis P Radermecker
[Ezetimibe (Ezetrol) in patients with diabetes].
Revue médicale de Liège 2009;64(12):606-11.
2009: André J Scheen
[Rivaroxaban (Xarelto): new anticoagulant inhibitor of factor Xa].
Revue médicale de Liège 2009;64(10):538-43.
2009: Jean-Marie Krzesinski; André J Scheen
[Sevikar or Forzaten: olmesartan medoxomil and amlodipine besylate fixed combination in the treatment of hypertension].
Revue médicale de Liège 2009;64(9):468-73.
2009: André J Scheen; Pierre J Lefebvre
[Insulin glargine and cancer: a storm in a glass of water?].
Revue médicale de Liège 2009;64(9):440-5.
2009: Régis P Radermecker; E Renard; André J Scheen
Circulating insulin antibodies: influence of continuous subcutaneous or intraperitoneal insulin infusion, and impact on glucose control.
Diabetes/metabolism research and reviews 2009;25(6):491-501.
2009: E Beck; N Esser; Nicolas Paquot; André J Scheen
[Metabolically obese normal-weight individuals and metabolically healthy, but obese, subjects].
Revue médicale suisse 2009;5(214):1644-6, 1648-9.
2009: A Nyssen; Victor Legrand; André J Scheen
[Prevention of restenosis and of cardiac events after coronary angioplasty in diabetics].
Revue médicale suisse 2009;5(214):1638-43.
2009: André J Scheen; Gustave Moonen
[Practical advices for writing a case report].
Revue médicale de Liège 2009;64(7-8):418-22.
2009: JC Philips; M Marchand; André J Scheen
Pulse pressure and cardiovascular autonomic neuropathy according to duration of type 1 diabetes.
Diabetes/metabolism research and reviews 2009;25(5):442-51.
2009: André J Scheen
Voglibose for prevention of type 2 diabetes mellitus.
Lancet 2009;373(9675):1579-80.
2009: André J Scheen
[New advances in therapeutic use of monoclonal antibodies].
Revue médicale de Liège 2009;64(5-6):253-6.
2009: André J Scheen
[International classification of various types of monoclonal antibodies].
Revue médicale de Liège 2009;64(5-6):244-7.
2009: Pierre Delanaye; Etienne Cavalier; Régis P Radermecker; Nicolas Paquot; Gisèle Depas; Jean-Paul Chapelle; André J Scheen; Jean-Marie Krzesinski
Estimation of GFR by different creatinine- and cystatin-C-based equations in anorexia nervosa.
Clinical nephrology 2009;71(5):482-91.
2009: André J Scheen; Jean-Marie Krzesinski
[Fixed combination perindopril-amlodipine (Coveram) in the treatment of hypertension and coronary heart disease].
Revue médicale de Liège 2009;64(4):223-7.
2009: A Nyssen; Victor Legrand; André J Scheen
[Incidence of restenosis and cardiac events after coronary angioplasty in diabetic patients: reduction by systemic pharmacological approaches].
Revue médicale de Liège 2009;64(4):192-8.
2009: André J Scheen
Progression of the prevalence of metabolic syndrome in normal-weight US subjects.
Archives of internal medicine 2009;169(6):636-7; author reply 637.
2009: André J Scheen; Nicolas Paquot
[Vildagliptin (Galvus) and fixed combination vildagliptine-metformin (Eucreas) in the treatment of type 2 diabetes].
Revue médicale de Liège 2009;64(3):161-7.
2009: N Esser; André J Scheen
[Metabolically normal obese subjects].
Revue médicale de Liège 2009;64(3):148-57.
2009: JC Philips; André J Scheen
[Insulin detemir in the predictive study: results in patients with type 1 diabetes in the Belgian cohort].
Revue médicale de Liège 2009;64(3):124-30.
2009: J De Flines; Régis P Radermecker; BJ Jandrain; André J Scheen
[Optimisation of pharmacological therapy in a patient with a newly diagnosed type 2 diabetes].
Revue médicale de Liège 2009;64(2):109-14.
2009: André J Scheen; Nicolas Paquot
Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders.
Best practice & research. Clinical endocrinology & metabolism 2009;23(1):103-16.
2009: André J Scheen
The endocannabinoid system: a promising target for the management of type 2 diabetes.
Current protein & peptide science 2009;10(1):56-74.
2009: E Beck; André J Scheen
[Metabolically obese with normal weight individuals: an intriguing phenotype].
Revue médicale de Liège 2009;64(1):16-24.
2008: André J Scheen
[JUPITER: reduction by rosuvastatin of cardiovascular events and mortality in healthy subjects without hyperlipidaemia but with elevated C-reactive protein].
Revue médicale de Liège 2008;63(12):749-53.
2008: André J Scheen
New therapeutic approaches in type 2 diabetes.
Acta clinica Belgica 2008;63(6):402-7.
2008: André J Scheen
[Drug selection guided by known and newly diagnosed comorbidities in a multi-risk patient].
Revue médicale de Liège 2008;63(11):693-6.
2008: Régis P Radermecker; André J Scheen
[Biphasic insulin aspart (NovoMix 50)].
Revue médicale de Liège 2008;63(11):688-92.
2008: A Nyssen; Victor Legrand; André J Scheen
[Benefit-risk ratio of coronary drug-eluting stents: 2nd part: evaluation in the diabetic population].
Revue médicale de Liège 2008;63(11):654-61.
2008: André J Scheen; Nicolas Paquot; Pierre J Lefebvre
[United Kingdom Prospective Diabetes Study (UKPDS): 10 years later].
Revue médicale de Liège 2008;63(10):624-9.
2008: André J Scheen; Luc A Piérard; Jean-Marie Krzesinski
[Aliskiren (Rasilez), direct renin inhibitor].
Revue médicale de Liège 2008;63(9):564-9.
2008: A Nyssen; Victor Legrand; André J Scheen
[Benefit-risk ratio of coronary drug-eluting stents. 1st part: evaluation in the global population].
Revue médicale de Liège 2008;63(9):542-8.
2008: André J Scheen; Nicolas Paquot; Luc F Van Gaal
[CB1 receptor inhibition and glucose metabolism: role of rimonabant in type 2 diabetes].
Revue médicale suisse 2008;4(168):1812-7.
2008: Astrid Nyssen; Victor Legrand; André J Scheen
[Coronary drug-eluting stents in diabetic patients].
Revue médicale suisse 2008;4(168):1806-10.
2008: Caroline M Wallemacq; André J Scheen
[Therapeutic impact of screening for myocardial ischemia among asymptomatic type 2 diabetic subjects].
Revue médicale suisse 2008;4(168):1800-4.
2008: André J Scheen
[Don't forget about heart disease in women].
Revue médicale suisse 2008;4(168):1787-8.
2008: I Van Cauwenberge; JC Philips; André J Scheen
[Anaesthetic risk related to cardiac autonomic neuropathy in diabetic patients].
Revue médicale de Liège 2008;63(7-8):488-93.
2008: André J Scheen; Nicolas Paquot
Inhibitors of cannabinoid receptors and glucose metabolism.
Current opinion in clinical nutrition and metabolic care 2008;11(4):505-11.
2008: Luc F Van Gaal; André J Scheen; Aila Rissanen; Stephan Rössner; Corinne Hanotin; Olivier Ziegler
Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.
European heart journal 2008;29(14):1761-71.
2008: André J Scheen; Vincent Seutin; Luc F Van Gaal
[Endocannabinoid system in the brain...and elsewhere].
Revue médicale de Liège 2008;63(5-6):364-71.
2008: André J Scheen; Régis P Radermecker; B Sadzot
[Statin for the brain: update in 2008].
Revue médicale de Liège 2008;63(5-6):287-92.
2008: R R Radermecker; JC Philips; BJ Jandrain; Nicolas Paquot; Pierre J Lefèbvre; André J Scheen
[Brain, a gluco-dependent organ: toxic effects of hypoglycaemia and hyperglycaemia].
Revue médicale de Liège 2008;63(5-6):280-6.
2008: André J Scheen
CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.
Journal of neuroendocrinology 2008;20 Suppl 1():139-46.
2008: André J Scheen
Do thiazolidinediones increase the risk of congestive heart failure and cardiovascular death?
Nature clinical practice. Endocrinology & metabolism 2008;4(5):260-1.
2008: André J Scheen; Jean-Marie Krzesinski
[ONTARGET: similar protection of telmisartan and ramipril and lack of benefit of combined therapy in patients at high risk for vascular events].
Revue médicale de Liège 2008;63(4):213-9.
2008: Florence Schleich; Jean-Marie Krzesinski; Luc A Piérard; André J Scheen
[How I treat... by optimizing the blockade of the renin-angiotensin-aldosterone system].
Revue médicale de Liège 2008;63(4):174-81.
2008: André J Scheen
Medications in the kidney.
Acta clinica Belgica 2008;63(2):76-80.
2008: André J Scheen; Luc F Van Gaal
[Medication of the month... Exenatide (Byetta) incretinomimetic in the treatment of type 2 diabetes after failure and as add-on therapy to oral agents].
Revue médicale de Liège 2008;63(3):158-65.
2008: André J Scheen
The future of obesity: new drugs versus lifestyle interventions.
Expert opinion on investigational drugs 2008;17(3):263-7.
2008: André J Scheen; Luc F Van Gaal
[Sitagliptine (Januvia): incretin enhancer potentiating insulin secretion for the treatment of type 2 diabetes].
Revue médicale de Liège 2008;63(2):105-9.
2008: JC Philips; M Marchand; André J Scheen
Squatting amplifies pulse pressure increase with disease duration in patients with type 1 diabetes.
Diabetes care 2008;31(2):322-4.
2008: Pierre Delanaye; Etienne Cavalier; Régis P Radermecker; Nicolas Paquot; Gisèle Depas; Jean-Paul Chapelle; André J Scheen; Jean-Marie Krzesinski
Cystatin C or creatinine for detection of stage 3 chronic kidney disease in anorexia nervosa.
Nephron. Clinical practice 2008;110(3):c158-63.
2008: Delphine Legrand; André J Scheen
[Multiple risk factors and drug interactions leading to severe lactic acidosis].
Thérapie 2008;63(1):69-70.
2008: André J Scheen; L F Van Gaal
[Medication of the month. Rimonabant (Acomplia): first CB1 receptor antagonist of the endocannabinoid system].
Revue médicale de Liège 2008;63(1):50-5.
2007: André J Scheen
Cannabinoid-1 receptor antagonists in type-2 diabetes.
Best practice & research. Clinical endocrinology & metabolism 2007;21(4):535-53.
2007: I Schrouff; Hernan Valdes-Socin; Frédéric Frippiat; Laurence de Leval; DJ Soyeur; Marc Albert Radermecker; André J Scheen
[Isolated tricuspid valve endocarditis as a cause of fever of unknown origin].
Revue médicale de Liège 2007;62(11):654-8.
2007: André J Scheen; Jean-Marie Krzesinski
[Clinical trial of the month. ADVANCE: improved survival and better vascular and renal outcomes with a fixed combination of perindopril and indapamide in patients with type 2 diabetes].
Revue médicale de Liège 2007;62(10):639-43.
2007: D A Legrand; André J Scheen
[Aspirin resistance in diabetic patients: laboratory entity or clinical reality?].
Revue médicale de Liège 2007;62(10):610-5.
2007: André J Scheen; Régis P Radermecker
[Drug of the month. Ezetimibe/simvastatin tablet (Inegy)].
Revue médicale de Liège 2007;62(9):585-90.
2007: André J Scheen; J De Flines; Nicolas Paquot
[What about the controversy regarding rosiglitazone].
Revue médicale de Liège 2007;62(9):560-5.
2007: D Legrand; André J Scheen
[Does coffee protect against type 2 diabetes?].
Revue médicale de Liège 2007;62(9):554-9.
2007: Luc F Van Gaal; André J Scheen; Xavier Formiguera
The safety of obesity drugs.
Expert opinion on drug safety 2007;6(5):475-6; author reply 477-8.
2007: André J Scheen; Régis P Radermecker; JC Philips; Nicolas Paquot
[Incretin mimetics and incretin enhancers for the treatment of type 2 diabetes].
Revue médicale suisse 2007;3(122):1884, 1886-8.
2007: J De Flines; André J Scheen
[Glitazones and congestive heart failure: update on PROactive, ADOPT, DREAM and RECORD clinical trials].
Revue médicale suisse 2007;3(122):1876, 1878-83.
2007: André J Scheen
[Does a "therapeutic memory" exist in cardiovascular prevention?].
Revue médicale suisse 2007;3(122):1864-6, 1868-9.
2007: André J Scheen
[Prevention of cardiovascular diseases].
Revue médicale suisse 2007;3(122):1859-60.
2007: André J Scheen
[Evaluation of insulinosecretion and insulinosensitivity].
Thérapie 2007;62(4):311-8.
2007: Régis P Radermecker; André J Scheen
Allergy reactions to insulin: effects of continuous subcutaneous insulin infusion and insulin analogues.
Diabetes/metabolism research and reviews 2007;23(5):348-55.
2007: André J Scheen; Luc F Van Gaal
Rimonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes.
European heart journal 2007;28(11):1401-2; author reply 1402.
2007: André J Scheen
[Epilogue of the "therapeutic memory"...].
Revue médicale de Liège 2007;62(5-6):471-3.
2007: M Rorive; J De Flines; Nicolas Paquot; Arnaud De Roover; André J Scheen
[Recent advances in the management of obesity].
Revue médicale de Liège 2007;62(5-6):329-34.
2007: André J Scheen; Régis P Radermecker; J De Flines; J Ducobu
[Recent treatment perspectives in lipidology].
Revue médicale de Liège 2007;62(5-6):324-8.
2007: André J Scheen
[Glucagon-like peptide-1 (GLP-1), new target for the treatment of type 2 diabetes].
Revue médicale de Liège 2007;62(4):217-21.
2007: André J Scheen; Delphine Legrand
Platelet dysfunction associated with insulin therapy in patients with type 2 diabetes: please do not throw the baby out with the bathwater!
Journal of the American College of Cardiology 2007;49(5):628; author reply 628-9.
2007: J De Flines; André J Scheen
[Congestive heart failure and diabetes mellitus: an intricated relationship].
Revue médicale de Liège 2007;62(2):112-7.
2007: André J Scheen; L F Van Gaal
[Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes].
Revue médicale de Liège 2007;62(2):81-5.
2007: DA Legrand; Régis P Radermecker; M-P Stassen; DJ Soyeur; M-A Radermecker; André J Scheen
Staphylococcus aureus endocarditis in a diabetic woman treated by continuous subcutaneous insulin infusion.
Diabetes & metabolism 2007;33(1):79-81.
2007: André J Scheen
Antidiabetic agents in subjects with mild dysglycaemia: prevention or early treatment of type 2 diabetes?
Diabetes & metabolism 2007;33(1):3-12.
2007: André J Scheen; Régis P Radermecker; JC Philips; M Rorive; J De Flines; P Ernest; Nicolas Paquot
[Therapy of type 2 diabetes: between insulin sensitizers and insulin secreting agents].
Revue médicale de Liège 2007;62 Spec No():40-6.
2007: André J Scheen
[Diabetes mellitus: from clinical knowledge to public health concern].
Journal de la Société de biologie 2007;201(2):133-40.
2007: André J Scheen
[ADOPT study: which first-line glucose-lowering oral medication in type 2 diabetes?].
Revue médicale de Liège 2007;62(1):48-52.
2007: Régis P Radermecker; Gérald E Piérard; André J Scheen
Lipodystrophy reactions to insulin: effects of continuous insulin infusion and new insulin analogs.
American journal of clinical dermatology 2007;8(1):21-8.
2007: André J Scheen
Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide.
Clinical pharmacokinetics 2007;46(2):93-108.
2007: André J Scheen
Pharmacokinetic interactions with thiazolidinediones.
Clinical pharmacokinetics 2007;46(1):1-12.
2006: André J Scheen; Delphine Legrand
Aspirin and clopidogrel resistance in patients with diabetes mellitus.
European heart journal 2006;27(23):2900; author reply 2900-1.
2006: André J Scheen; Nick Finer; Priscilla Hollander; Michael D Jensen; Luc F Van Gaal
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study.
Lancet 2006;368(9548):1660-72.
2006: André J Scheen
[DREAM study: prevention of type 2 diabetes with ramipril and/or rosiglitazone in persons with dysglycaemia but no cardiovascular desease].
Revue médicale de Liège 2006;61(10):728-32.
2006: DA Legrand; André J Scheen
[Aspirin for primary prevention of cardiovascular diseases in diabetic patients: focus on gender difference and insulin resistance].
Revue médicale de Liège 2006;61(10):682-90.
2006: André J Scheen
[The CHARISMA study: in search of the best antiplatelet strategy for cardiovascular prevention].
Revue médicale de Liège 2006;61(9):656-61.
2006: André J Scheen
[Increasing cost of insulin therapy in Belgium. From a critical analysis of the situation to a search for practical solutions].
Revue médicale de Liège 2006;61(9):617-22.
2006: André J Scheen; L G Van Gaal; J P Després; X Pi-Sunyer; A Golay; C Hanotin
[Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies].
Revue médicale suisse 2006;2(76):1916-23.
2006: Régis P Radermecker; André J Scheen
[Distinction between good synthesizer and good absorber patients to optimize cholesterol-lowering therapy].
Revue médicale suisse 2006;2(76):1910-5.
2006: DA Legrand; André J Scheen
[Aspirin therapy for cardiovascular prevention in the diabetic patient: what have we learned from the evidence?].
Revue médicale suisse 2006;2(76):1904-8.
2006: J De Flines; André J Scheen
[Diabetes mellitus and congestive heart failure: physiopathology and treatment].
Revue médicale suisse 2006;2(76):1893-6, 1898-900.
2006: JC Philips; M Marchand; Laurent Weekers; André J Scheen
[Arterial pulse pressure in relation to the duration of type 1 diabetes: a cross-sectional controlled study].
Archives des maladies du coeur et des vaisseaux 2006;99(7-8):683-6.
2006: André J Scheen; A Parada; Didier Giet
[Advices for a better drug prescription].
Revue médicale de Liège 2006;61(5-6):488-93.
2006: André J Scheen
[Drug interactions: from theory to practice].
Revue médicale de Liège 2006;61(5-6):471-82.
2006: Nicolas Paquot; André J Scheen
[Role of micronutrients in medicine].
Revue médicale de Liège 2006;61(5-6):464-70.
2006: Régis P Radermecker; André J Scheen
[Effects of glimepiride (Amarylle) in type 2 diabetic patients: results of the Belgian study RECORD in general medicine].
Revue médicale de Liège 2006;61(5-6):423-9.
2006: Régis P Radermecker; André J Scheen
Serum plant sterols and atherosclerosis: is there a place for statin-ezetimibe combination?
Journal of the American College of Cardiology 2006;47(7):1496-7; author reply 1497-8.
2006: André J Scheen
[Clinical study of the month: ASTEROID: regression of coronary atherosclerosis with rosuvastatin at a maximal daily dose of 40 mg].
Revue médicale de Liège 2006;61(4):267-72.
2006: André J Scheen
[How I explore...outcomes in clinical trials: comments about recent studies of cardiovascular prevention].
Revue médicale de Liège 2006;61(4):260-6.
2006: Gérald E Piérard; André J Scheen
[Basic initiatory glossary to clinical research].
Revue médicale de Liège 2006;61(3):190-4.
2006: André J Scheen
[The IDEAL study comparing simvastatin 20-40 mg versus atorvastatin 80 mg for secondary prevention after myocardial infarction: between two ideas of the ideal].
Revue médicale de Liège 2006;61(1):53-9.
2006: André J Scheen; Françoise Luyckx; Pierre J Lefebvre
[How to explore...the metabolic syndrome by its new IDF definition].
Revue médicale de Liège 2006;61(1):48-52.
2005: R P Radermecker; André J Scheen
[Field, a randomized clinical trial of cardiovascular prevention with fenofibrate in type 2 diabetes].
Revue médicale de Liège 2005;60(12):957-61.
2005: André J Scheen
Diabetes mellitus in the elderly: insulin resistance and/or impaired insulin secretion?
Diabetes & metabolism 2005;31 Spec No 2():5S27-5S34.
2005: André J Scheen; Pierre J Lefèbvre
[Proactive study: secondary cardiovascular prevention with pioglitazione in type 2 diabetic patients].
Revue médicale de Liège 2005;60(11):896-901.
2005: André J Scheen; Régis P Radermecker; JC Philips; Nicolas Paquot
[Insulin detemir (Levemir)].
Revue médicale de Liège 2005;60(10):814-9.
2005: André J Scheen; B Sadzot
[Which indications for statins besides their cholesterol-lowering effect?].
Revue médicale suisse 2005;1(30):1954, 1956-9.
2005: André J Scheen
[From the very valuable therapy, to the high cost of a new drug: a growing hiatus].
Revue médicale suisse 2005;1(30):1931-2.
2005: André J Scheen; Pierre J Lefèbvre
[Diabetes mellitus: epilogue].
Revue médicale de Liège 2005;60(5-6):628-31.
2005: F Nobels; André J Scheen
[The role of diabetes convention centres in Belgium].
Revue médicale de Liège 2005;60(5-6):619-23.
2005: André J Scheen; L F Van Gaal
[Type 2 diabetes, in the heart of the metabolic syndrome: plea for a global approach].
Revue médicale de Liège 2005;60(5-6):566-71.
2005: JC Philips; M Marchand; André J Scheen
[Diabetic cardiac autonomic neuropathy].
Revue médicale de Liège 2005;60(5-6):498-504.
2005: André J Scheen; Marc De Hert
[Drug-induced diabetes mellitus: the exemple of atypical antipsychotics].
Revue médicale de Liège 2005;60(5-6):455-60.
2005: V Thielen; Régis P Radermecker; JC Philips; Nicolas Paquot; André J Scheen
[Hereditary hemochromatosis and diabetes mellitus: diagnostic approach and clinical evolution].
Revue médicale de Liège 2005;60(5-6):448-54.
2005: André J Scheen
[Similar reduction in new cases of type 2 diabetes with angiotensin receptor blocker and ACE inhibitor: comparison of meta-analyses of prospective randomised trials].
Revue médicale de Liège 2005;60(5-6):424-8.
2005: JC Philips; André J Scheen
[Insulin therapy in type 2 diabetes].
Revue médicale de Liège 2005;60(5-6):419-23.
2005: André J Scheen
[Towards a tripple oral therapy in the pharmacological treatment of type 2 diabetes?].
Revue médicale de Liège 2005;60(5-6):414-8.
2005: André J Scheen; Nicolas Paquot
[Insulin sensitizers].
Revue médicale de Liège 2005;60(5-6):409-13.
2005: André J Scheen; Didier Giet
[Prevention of type 2 diabetes: a new public health challenge].
Revue médicale de Liège 2005;60(5-6):383-90.
2005: M Rorive; MR Letiexhe; André J Scheen; O Ziegler
[Obesity and type 2 diabetes].
Revue médicale de Liège 2005;60(5-6):374-82.
2005: Régis P Radermecker; M P Hermans; DA Legrand; André J Scheen
[Continuous subcutaneous insulin infusion with portable pumps].
Revue médicale de Liège 2005;60(5-6):329-34.
2005: André J Scheen; HE Kulbertus
[Diabetes mellitus: an example of a well-considered disease. Introduction].
Revue médicale de Liège 2005;60(5-6):269-72.
2005: Luc F Van Gaal; Aila Rissanen; André J Scheen; Olivier Ziegler; Stephan Rössner
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.
Lancet 2005;365(9468):1389-97.
2005: André J Scheen
["Treating to New Targets": plea for a LDL cholesterol target of or below 75 mg/dl in any patient with coronary heart disease].
Revue médicale de Liège 2005;60(4):264-7.
2005: André J Scheen; MR Letiexhe; M Rorive; J De Flines; Françoise Luyckx; Claude Desaive
[Bariatric surgery: 10-year results of the Swedish Obese Subjects Study].
Revue médicale de Liège 2005;60(2):121-5.
2005: André J Scheen; Nicolas Paquot
[PPAR-gamma receptors, new therapeutic target in metabolic and cardiovascular diseases].
Revue médicale de Liège 2005;60(2):89-95.
2005: André J Scheen
Drug interactions of clinical importance with antihyperglycaemic agents: an update.
Drug safety : an international journal of medical toxicology and drug experience 2005;28(7):601-31.
2004: André J Scheen; Fabian Warzée; Victor Legrand
Drug-eluting stents: meta-analysis in diabetic patients.
European heart journal 2004;25(23):2167-8; author reply 2168-9.
2004: André J Scheen; HE Kulbertus
[Interheart: nine risk factors predict nine out of ten myocardial infarctions].
Revue médicale de Liège 2004;59(11):676-9.
2004: André J Scheen
[Withdrawal of rofecoxib (Vioxx): what about cardiovascular safety of COX-2 selective non-steroidal anti-inflammatory drugs?].
Revue médicale de Liège 2004;59(10):565-9.
2004: André J Scheen
VALUE: analysis of results.
Lancet 2004;364(9438):932-3; author reply 935.
2004: André J Scheen; Régis P Radermecker; JC Philips
[Effects of intensive insulin therapy after an acute myocardial infarction in patients with type 2 diabetes: results of the DIGAMI-2 trial].
Revue médicale de Liège 2004;59(9):534-9.
2004: André J Scheen
[How I explore...the absolute cardiovascular risk at 10 years: from Framingham 1998 to SCORE 2003].
Revue médicale de Liège 2004;59(7-8):460-6.
2004: André J Scheen; Fabian Warzée
Diabetes is still a risk factor for restenosis after drug-eluting stent in coronary arteries.
Diabetes care 2004;27(7):1840-1.
2004: André J Scheen; Régis P Radermecker; JC Philips
[Optimizing the managment of patients with diabetes mellitus: selected clinical trials from the 2004 Congress of the American Diabetes Association].
Revue médicale de Liège 2004;59(6):407-12.
2004: André J Scheen
[New advances in drug therapy in 2003-2004].
Revue médicale de Liège 2004;59(6):385-402.
2004: MR Letiexhe; Claude Desaive; Pierre J Lefèbvre; André J Scheen
Intact cross-talk between insulin secretion and insulin action after postgastroplasty recovery of ideal body weight in severely obese patients.
International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity 2004;28(6):821-3.
2004: J Gerard; André J Scheen
[Porphyrias, a rare cause of acute abdominal pain].
Revue médicale de Liège 2004;59(5):270-3.
2004: Régis P Radermecker; André J Scheen
[Hypoglycaemic coma, a feared paroxysmal phenomenon in type 1 diabetic patient].
Revue médicale de Liège 2004;59(5):265-9.
2004: André J Scheen; Michel Malaise
[Valdecoxib (Bextra)].
Revue médicale de Liège 2004;59(4):251-4.
2004: André J Scheen
[Ezetimibe (Ezetrol)].
Revue médicale de Liège 2004;59(4):246-50.
2004: André J Scheen; HE Kulbertus
[Clinical study of the month. REVERAL and PROVE-IT: confirmation of the concept " the lower, the better" for cholesterol therapy in patients with coronary heart disease].
Revue médicale de Liège 2004;59(3):167-73.
2004: André J Scheen
[Medication of the month. Insulin glargine (Lantus)].
Revue médicale de Liège 2004;59(2):110-4.
2004: Jaime A Davidson; André J Scheen; Harry C S Howlett
Tolerability profile of metformin/glibenclamide combination tablets (Glucovance): a new treatment for the management of type 2 diabetes mellitus.
Drug safety : an international journal of medical toxicology and drug experience 2004;27(15):1205-16.
2004: André J Scheen
Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.
Drugs 2004;64(22):2537-65.
2004: André J Scheen
Combined thiazolidinedione-insulin therapy: should we be concerned about safety?
Drug safety : an international journal of medical toxicology and drug experience 2004;27(12):841-56.
2004: André J Scheen
[Drug of the month. Rosuvastatin (Crestor)].
Revue médicale de Liège 2004;59(1):56-9.
2004: V Thielen; Nicolas Paquot; André J Scheen
[Hematochromatosis and diabetes].
Revue médicale de Liège 2004;59(1):29-31.
2003: André J Scheen
Pathophysiology of type 2 diabetes.
Acta clinica Belgica 2003;58(6):335-41.
2003: André J Scheen; V Legrand
[Clinical study of the month. The EUROPA study: cardiovascular protection with perindopril in patients with stable coronary heart disease].
Revue médicale de Liège 2003;58(11):713-6.
2003: André J Scheen
[Medication of the month. Gliclazide modified release (Uni Diamicron)].
Revue médicale de Liège 2003;58(10):641-5.
2003: André J Scheen
Treatment of type 2 diabetes.
Acta clinica Belgica 2003;58(5):318-24.
2003: André J Scheen
[Clinical study of the month. Premature interruption of ASCOT and CARDS clinical trials of cardiovascular prevention with atorvastatin in patients with arterial hypertension or diabetes mellitus: compromise between ethics and statistics in evidence-based medicine ].
Revue médicale de Liège 2003;58(9):585-90.
2003: André J Scheen
[Medication of the month. Vardenafil (Levitra)].
Revue médicale de Liège 2003;58(9):576-9.
2003: E Lebas; Nicolas Paquot; André J Scheen
[Adiponectin: a new adipocytokine].
Revue médicale de Liège 2003;58(9):554-8.
2003: André J Scheen
Preventing, delaying, or masking type 2 diabetes with metformin in the diabetes prevention program?
Diabetes care 2003;26(9):2701; author reply 2701-3.
2003: David Magis; BJ Jandrain; André J Scheen
[Alcohol, insulin sensitivity and diabetes].
Revue médicale de Liège 2003;58(7-8):501-7.
2003: André J Scheen; Françoise Luyckx
[Metabolic syndrome: definitions and epidemiological data].
Revue médicale de Liège 2003;58(7-8):479-84.
2003: André J Scheen
[Medication of the month. Glucovance in type 2 diabetes, a fixed combination of metformin-glibenclamide for the treatment of a bipolar metabolic disease].
Revue médicale de Liège 2003;58(6):448-52.
2003: Régis P Radermecker; BJ Jandrain; Nicolas Paquot; JC Philips; E Contessi; M Lavigne; A M Rinaldi; André J Scheen
[Prevention of hypoglycemia in patients with type 1 diabetes].
Revue médicale de Liège 2003;58(6):361-8.
2003: Ulysse J Gaspard; André J Scheen; Jan Endrikat; C Buicu; P Lefebvre; Christoph Gerlinger; Renate Heithecker
A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism.
Contraception 2003;67(6):423-9.
2003: Nicolas Paquot; André J Scheen
[Prevention of cardiovascular disease in type 2 diabetes].
Revue médicale de Liège 2003;58(5):271-4.
2003: André J Scheen; Nicolas Paquot
[Blood glucose control and prevention of microangiopathy and macroangiopathy in type 2 diabetes].
Revue médicale de Liège 2003;58(5):265-70.
2003: JC Philips; André J Scheen
[Prevention strategies of type 1 diabetes: the focus in 2003].
Revue médicale de Liège 2003;58(4):211-9.
2003: André J Scheen; MR Letiexhe; Ph Ernest
[Prevention of type 2 diabetes: lifestyle changes or pharmacological interventions?].
Revue médicale de Liège 2003;58(4):206-10.
2003: André J Scheen; HE Kulbertus
[Statins for cardiovascular prevention: is there still a place for cholesterol measurement?].
Revue médicale de Liège 2003;58(4):191-7.
2003: Régis P Radermecker; David Magis; J L Sélam; André J Scheen
[How I explore...glycemic kinetics by continuous glucose monitoring].
Revue médicale de Liège 2003;58(3):164-7.
2003: André J Scheen; G Bruwier; H Schmitt
[Optimizing the management of type 2 diabetics: results of the "DREAM" study in general practice].
Revue médicale de Liège 2003;58(3):139-46.
2003: Régis P Radermecker; JC Philips; André J Scheen
[How I treat...severe hypoglycemia in a diabetic patient].
Revue médicale de Liège 2003;58(3):119-22.
2003: André J Scheen; F Estrella
[Clinical trial of the month. The STENO-2 study: a plea for global and intensive management of the type 2 diabetic patient].
Revue médicale de Liège 2003;58(2):109-11.
2003: JC Philips; Régis P Radermecker; André J Scheen
[Islet cell transplantation: a step toward curing diabetes?].
Revue médicale de Liège 2003;58(2):83-7.
2003: Oriane Martalo; Claudine Piérard-Franchimont; André J Scheen; Gérald E Piérard
[Skin diseases and obesity].
Revue médicale de Liège 2003;58(2):73-6.
2003: André J Scheen
Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?
Drugs 2003;63(10):933-51.
2003: HE Kulbertus; André J Scheen
[Clinical study of the month. The ALLHAT-LLT trial].
Revue médicale de Liège 2003;58(1):53-8.
2003: André J Scheen; J M Krzesinski
[Clinical study of the month. Which initial antihypertensive? Results from the ALLHAT trial].
Revue médicale de Liège 2003;58(1):47-52.
2002: HE Kulbertus; André J Scheen
[The PROSPER Study (PROspective study of pravastatin in the elderly at risk)].
Revue médicale de Liège 2002;57(12):809-13.
2002: André J Scheen; Ph Ernest
New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat.
Diabetes & metabolism 2002;28(6 Pt 1):437-45.
2002: André J Scheen; Françoise H Luyckx
Obesity and liver disease.
Best practice & research. Clinical endocrinology & metabolism 2002;16(4):703-16.
2002: André J Scheen
Acarbose for type 2 diabetes prevention.
Lancet 2002;360(9344):1516; author reply 1517.
2002: André J Scheen
[Therapeutic advances in 2002 (1)].
Revue médicale de Liège 2002;57(11):719-31.
2002: JC Philips; André J Scheen
[Info-congress. Study of the prevention of type 1 diabetes with nicotinamide: positive lessons of a negative clinical trial (ENDIT)].
Revue médicale de Liège 2002;57(10):672-5.
2002: André J Scheen
[Info-congress. Prevention of type 2 diabetes in obese patients: first results with orlistat in the XENDOS study].
Revue médicale de Liège 2002;57(9):617-21.
2002: David Magis; I Geronooz; André J Scheen
[Smoking, insulin resistance and type 2 diabetes].
Revue médicale de Liège 2002;57(9):575-81.
2002: André J Scheen
[Clinical study of the month. The LIPS study: fluvastatin for prevention of cardiac events following percutaneous coronary angioplasty].
Revue médicale de Liège 2002;57(7):479-82.
2002: André J Scheen
[Prevention of type II diabetes by inhibiting the renin-angiotensin system].
Revue médicale de Liège 2002;57(7):449-52.
2002: JC Philips; André J Scheen
[Clinical study of the month. Attempt at preservation of B cells during the initial phase of type 1 diabetes: negative results with ultralente insulin, but promising results with an anti-CD3 monoclonal antibody].
Revue médicale de Liège 2002;57(6):413-7.
2002: André J Scheen
[Pitfalls and precautions concerning the use of conventional oral antidiabetic drugs].
Revue médicale de Liège 2002;57(5):352-6.
2002: André J Scheen
[One type of diabetes may conceal another].
Revue médicale de Liège 2002;57(5):267-9.
2002: André J Scheen
[Clinical study of the month. The LIFE study: cardiovascular protection of hypertensive patients by losartan].
Revue médicale de Liège 2002;57(4):240-4.
2002: André J Scheen
[Medication of the month. Rosiglitazone (Avandia)].
Revue médicale de Liège 2002;57(4):236-9.
2002: André J Scheen; MR Letiexhe; I Geronooz; Nicolas Paquot; BJ Jandrain
[Postprandial hyperglycemia. II. Pharmacological approaches].
Revue médicale de Liège 2002;57(4):196-201.
2002: André J Scheen; Nicolas Paquot; BJ Jandrain; Pierre J Lefèbvre
[Postprandial hyperglycemia. I. Physiopathology, clinical consequences and dietary management].
Revue médicale de Liège 2002;57(3):138-41.
2002: Luc Van Gaal; André J Scheen
Are all glitazones the same?
Diabetes/metabolism research and reviews 2002;18 Suppl 2():S1-4.
2002: Nicolas Paquot; André J Scheen; Mirjam Dirlewanger; Pierre J Lefèbvre; Luc Tappy
Hepatic insulin resistance in obese non-diabetic subjects and in type 2 diabetic patients.
Obesity research 2002;10(3):129-34.
2002: André J Scheen; Nicolas Paquot; BJ Jandrain
[How I explore ... the risk of a patient developing type 2 diabetes].
Revue médicale de Liège 2002;57(2):113-5.
2002: André J Scheen; Pierrè J Lefèbvre
Potential pharmacokinetics interference between alpha-glucosidase inhibitors and other oral antidiabetic agents.
Diabetes care 2002;25(1):247-8.
2001: André J Scheen
[Clinical study of the month. Toxicity of hyperglycemia in intensive care and beneficial effects of optimized insulin therapy].
Revue médicale de Liège 2001;56(12):859-61.
2001: J De Flines; MR Letiexhe; Claude Desaive; André J Scheen
[Clinical case of the month. Natural history of morbid obesity: towards insulin-requiring type 2 diabetes and reversal after bariatric surgery].
Revue médicale de Liège 2001;56(12):816-22.
2001: André J Scheen
[Info-congress. The Cochrane collaboration, a key role in evidence-based medicine].
Revue médicale de Liège 2001;56(11):796-8.
2001: André J Scheen
[Pharma-clinics medication of the month. Nebivolol (Nobiten)].
Revue médicale de Liège 2001;56(11):788-91.
2001: André J Scheen
[Info-Meeting. Pharmacologic prevention of the progression from impaired glucose tolerance to type 2 diabetes: favorable effects of metformin and acarbose].
Revue médicale de Liège 2001;56(10):727-30.
2001: André J Scheen; I Geronooz; JC Philips; M Marchand
[Image of the month. Loss of respiratory sinus arrhythmia in diabetic autonomic neuropathy].
Revue médicale de Liège 2001;56(10):669-70.
2001: André J Scheen
[Pharma-clinics. Medication of the month. Sibutramine (Reductil)].
Revue médicale de Liège 2001;56(9):656-9.
2001: André J Scheen; JC Philips; Françoise Luyckx; Nicolas Paquot; BJ Jandrain
[How I explore ... the different forms of sugar diabetes: clinical and biological differental diagnosis].
Revue médicale de Liège 2001;56(9):650-5.
2001: André J Scheen
[Current therapy 2001].
Revue médicale de Liège 2001;56(9):612-24.
2001: André J Scheen; I Geronooz; M Marchand
[Finapres, efficient technique in the assessment of orthostatic hypotension, autonomic neuropathy, and vaso-vagal syncope].
Revue médicale de Liège 2001;56(8):577-82.
2001: André J Scheen; JC Philips
[Info-congress. Insulin therapy for preventing type 1 diabetes in high-risk relatives: negative results of the "Diabetes Prevention Trial-Type 1"].
Revue médicale de Liège 2001;56(7):536-8.
2001: André J Scheen; M Rorive; MR Letiexhe; L Devoitille; BJ Jandrain
[Multidisciplinary management of the obese patient: example from the Obesity Center at the University of Liege].
Revue médicale de Liège 2001;56(7):474-9.
2001: André J Scheen
[Clinical study of the month. Prevention of type 2 diabetes in overweight patients with impaired glucose tolerance: efficiency of lifestyle changes].
Revue médicale de Liège 2001;56(6):463-5.
2001: André J Scheen
[Pharma-clinics. Medication of the month. Repaglinide (NovoNorm)].
Revue médicale de Liège 2001;56(6):456-9.
2001: André J Scheen
Thiazolidinediones and liver toxicity.
Diabetes & metabolism 2001;27(3):305-13.
2001: André J Scheen; J M Crielaard
[Guidelines for good practice of sports activities].
Revue médicale de Liège 2001;56(5):396-400.
2001: BJ Jandrain; André J Scheen
[Muscular exercise in the diabetic patient].
Revue médicale de Liège 2001;56(5):300-5.
2001: André J Scheen
[The insulin sensitivity concept].
Diabetes & metabolism 2001;27(2 Pt 2):193-200.
2001: André J Scheen; M Rorive; MR Letiexhe
[Physical exercise for preventing obesity, promoting weight loss and maintaining weight management].
Revue médicale de Liège 2001;56(4):244-7.
2001: André J Scheen; Nicolas Paquot
[Beneficial effects of physical activity on cardiovascular risk factors].
Revue médicale de Liège 2001;56(4):239-43.
2001: André J Scheen; BJ Jandrain
[Hormonal-metabolic adaptations to muscular exercise].
Revue médicale de Liège 2001;56(4):195-9.
2001: André J Scheen
[Pharmacy clinics. Medication of the month. Clopidogrel (Plavix)].
Revue médicale de Liège 2001;56(3):186-9.
2001: André J Scheen
Hepatotoxicity with thiazolidinediones: is it a class effect?
Drug safety : an international journal of medical toxicology and drug experience 2001;24(12):873-88.
2001: André J Scheen
[Clinical study of the month. After the storm over central anorectic agents, the "STORM" study of sibutramine].
Revue médicale de Liège 2001;56(1):56-8.
2001: André J Scheen
[Pharma-clinics. The drug of the month. Celecoxib (Celebrex)].
Revue médicale de Liège 2001;56(1):53-5.
2000: André J Scheen
[Meeting report. "MIRACL" study of "Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering"].
Revue médicale de Liège 2000;55(12):1064-6.
2000: André J Scheen
[Info-congress. Diabetes research: European diffusion from the Liege univesity].
Revue médicale de Liège 2000;55(10):960-7.
2000: André J Scheen
[Pharma-clinics. The drug of the month. Dipyridamole-acetylsalicylic acid combination (Aggrenox)].
Revue médicale de Liège 2000;55(10):957-9.
2000: Nicolas Paquot; Philippe Schneiter; André J Scheen; Pierre J Lefèbvre; L Tappy
Assessment of postprandial hepatic glycogen synthesis from uridine diphosphoglucose kinetics in obese and lean non-diabetic subjects.
International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity 2000;24(10):1297-302.
2000: André J Scheen
[Estrogen therapy after menopause and cardiovascular protection: discordance between epidemiologic observations and the results of therapeutic trials] .
Revue médicale de Liège 2000;55(9):886-8.
2000: Françoise Luyckx; André J Scheen
[How I study anomalies of glucose metabolism, insulin secretion and the insulin sensitivity with an oral glucose tolerance test].
Revue médicale de Liège 2000;55(9):881-5.
2000: André J Scheen
[Current therapeutics 2000].
Revue médicale de Liège 2000;55(9):852-61.
2000: André J Scheen
[Clinical study of the month. Prolonged insulin independence after transplantation of islets of Langerhans in a patient with type 1 diabetes: achievement of a dream?].
Revue médicale de Liège 2000;55(8):803-5.
2000: André J Scheen
[What's new in the domain of obesity?].
Revue médicale de Liège 2000;55(7):756-9.
2000: André J Scheen
[Pharma-clinics. The drug of the month. Rofecoxib (Vioxx)].
Revue médicale de Liège 2000;55(7):751-3.
2000: André J Scheen; M Rorive; F Estrella; Laurent Weekers; Pierre J Lefèbvre
[Guidelines for the treatment of arterial hypertension in diabetic patients].
Revue médicale de Liège 2000;55(5):376-82.
2000: Nicolas Paquot; André J Scheen; Pierre J Lefèbvre
[GLycemic control in the diabetic patient. Recommendations after the DCCT and UKPDI studies].
Revue médicale de Liège 2000;55(5):372-5.
2000: Françoise Luyckx; André J Scheen
[Recommendations for the treatment of obesity].
Revue médicale de Liège 2000;55(5):367-71.
2000: André J Scheen
[On the inapplicability of certain therapeutic guidelines in practice: the example of reimbursement for hypolipidemic agents in Belgium].
Revue médicale de Liège 2000;55(4):260-4.
2000: André J Scheen
[Evidence-based medicine. Input of controlled clinical trials].
Revue médicale de Liège 2000;55(4):216-9.
2000: Françoise Luyckx; Pierre J Lefebvre; André J Scheen
Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss.
Diabetes & metabolism 2000;26(2):98-106.
2000: André J Scheen
[Clinical study of the month. After DCCT, the EDIC study].
Revue médicale de Liège 2000;55(3):187-9.
2000: André J Scheen
[Pharma-clinics. Medication of the month. Glimepiride (Amarylle)].
Revue médicale de Liège 2000;55(3):184-6.
2000: Françoise Luyckx; S Delcour; JC Philips; André J Scheen
[The dosage of anti-GAD and anti-IA2 autoantibodies: an aid to the early diagnosis of type 1 diabetes].
Revue médicale de Liège 2000;55(3):169-75.
2000: André J Scheen; Pierre J Lefèbvre
Antiobesity pharmacotherapy in the management of type 2 diabetes.
Diabetes/metabolism research and reviews 2000;16(2):114-24.
2000: André J Scheen
[Clinical study of the month. The HOPE study, a two-by-two factorial clinical trial with contrasted results].
Revue médicale de Liège 2000;55(2):121-4.
2000: André J Scheen
[Pharmacy clinics. Medication of the month. Cerivastatin (Lipobay, Cholstat)].
Revue médicale de Liège 2000;55(2):117-20.
2000: André J Scheen
[Antioxidant vitamins in the prevention of cardiovascular diseases. 2nd part: results of clinical trials].
Revue médicale de Liège 2000;55(2):105-9.
2000: André J Scheen
[Pharma-clinics. Medication of the month. Moxonidine (Moxon)].
Revue médicale de Liège 2000;55(1):61-3.
2000: Dieudonné Nkoghe; André J Scheen
[Influenza: from vaccine prevention to antiviral therapy].
Revue médicale de Liège 2000;55(1):19-23.
2000: André J Scheen
[Antioxidant vitamins in the prevention of cardiovascular diseases. First part: epidemiologic studies].
Revue médicale de Liège 2000;55(1):11-8.
1999: Françoise Luyckx; André J Scheen; Claude Desaive; Albert Thiry; P J Lefébvre
Parallel reversibility of biological markers of the metabolic syndrome and liver steatosis after gastroplasty-induced weight loss in severe obesity.
The Journal of clinical endocrinology and metabolism 1999;84(11):4293.
1999: André J Scheen
[Info-Congress. The HOPE Study: Demonstration of the cardiovascular protection of ramipril, an ACE-inhibitor].
Revue médicale de Liège 1999;54(10):835-6.
1999: André J Scheen; F Estrella; Laurent Weekers
[Arterial hypertension and type 2 diabetes].
Revue médicale de Liège 1999;54(10):789-95.
1999: André J Scheen
[Clinical study of the month. Usefulness of increasing HDL cholesterol in secondary prevention of coronary heart disease: results of the VA-HIT study].
Revue médicale de Liège 1999;54(9):773-5.
1999: M Deschampheleire; Françoise Luyckx; André J Scheen
[Thyroid disorders and dyslipidemias].
Revue médicale de Liège 1999;54(9):746-50.
1999: André J Scheen
[New approaches in drug therapy 1999].
Revue médicale de Liège 1999;54(9):725-34.
1999: André J Scheen; Pierre J Lefèbvre
Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes.
Diabetes care 1999;22(9):1568-77.
1999: André J Scheen
[Study of the month. Long-term (1-2 years) clinical trials with orlistat, a new drug for the treatment of obesity].
Revue médicale de Liège 1999;54(8):707-9.
1999: Ulysse J Gaspard; O J Wery; André J Scheen; C Jaminet; Pierre J Lefebvre
Long-term effects of oral estradiol and dydrogesterone on carbohydrate metabolism in postmenopausal women.
Climacteric : the journal of the International Menopause Society 1999;2(2):93-100.
1999: André J Scheen
[Clinical study of the month. Prevention of cerebral vascular accidents in patients with atrial fibrillation].
Revue médicale de Liège 1999;54(6):561-3.
1999: André J Scheen; Françoise Luyckx
[How I evaluate ... a overweight or obese patient].
Revue médicale de Liège 1999;54(6):553-6.
1999: André J Scheen; MR Letiexhe; Pierre J Lefèbvre
Minimal influence of the time interval between injection of regular insulin and food intake on blood glucose control of type 1 diabetic patients on a basal-bolus insulin scheme.
Diabetes & metabolism 1999;25(2):157-62.
1999: André J Scheen; Françoise Luyckx; Claude Desaive; Pierre J Lefèbvre
Severe/extreme obesity: a medical disease requiring a surgical treatment?
Acta clinica Belgica 1999;54(3):154-61.
1999: I Geronooz; André J Scheen; Pierre J Lefèbvre
[Gestational diabetes: physiopathology and prognostic significance for the mother].
Revue médicale de Liège 1999;54(5):434-9.
1999: I Geronooz; André J Scheen; Jean-Michel Foidart
[Gestational diabetes: definition, screening and management].
Revue médicale de Liège 1999;54(5):429-33.
1999: André J Scheen
[Clinical study of the month. The CAPPP study: "The Captopril Prevention Project"].
Revue médicale de Liège 1999;54(3):197-9.
1999: André J Scheen; P Ernest; MR Letiexhe
[Pharmacy-clinics medication of the month. Orlistate (xenical)].
Revue médicale de Liège 1999;54(3):192-6.
1999: André J Scheen
[Pharmacy-clinic medication of the month. Naratriptan (naramig)].
Revue médicale de Liège 1999;54(3):189-91.
1999: Françoise Luyckx; André J Scheen; MR Letiexhe; Claude Desaive; J Gielen; Pierre J Lefèbvre
[How I treat ... an individual with severe obesity and metabolic abnormalities with gastroplasty].
Revue médicale de Liège 1999;54(3):138-42.
1999: André J Scheen; Georges Rorive; HE Kulbertus
[How I study individual coronary risk extrapolated over 10 years].
Revue médicale de Liège 1999;54(2):118-21.
1999: André J Scheen
[The epidemic of metabolic diseases, a major problem of public health].
Revue médicale de Liège 1999;54(2):87-94.
1999: André J Scheen; P J Lefébvre
Pharmacological treatment of obesity: present status.
International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity 1999;23 Suppl 1():47-53.
1999: André J Scheen
[Pharma-clinics. The drug of the month. Aceclofenac (Biofenac)].
Revue médicale de Liège 1999;54(1):62-4.
1999: André J Scheen
[Hypercholesterolemia-related cardiovascular risk: a continuum from a notion of normality, intervention threshold and therapeutic objectives].
Revue médicale de Liège 1999;54(1):17-21.
1999: André J Scheen
[Clinical study of the month. The LIPID study: "long-term intervention with pravastatin in ischaemic disease"].
Revue médicale de Liège 1999;54(1):2-3.
1998: J F Dandrifosse; AC Dandrifosse; Gérald E Piérard; André J Scheen; Guy Dandrifosse
[Necrolytic migratory erythema].
Revue médicale de Liège 1998;53(12):778-83.
1998: André J Scheen
[Drug clinics. How I treat a patient with a low concentration of HDL cholesterol].
Revue médicale de Liège 1998;53(12):727-31.
1998: André J Scheen
[Image of the month. What collapse!].
Revue médicale de Liège 1998;53(12):725-6.
1998: Françoise Luyckx; André J Scheen; Ana M Proenza; A Donny Strosberg; Pierre J Lefèbvre; JE Gielen
Influence of the A-->G (-3826) uncoupling protein-1 gene (UCP1) variant on the dynamics of body weight before and after gastroplasty in morbidly obese subjects.
International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity 1998;22(12):1244-5.
1998: André J Scheen
[Drug clinics. Drug of the month. Formoterol (Oxis turbohaler)].
Revue médicale de Liège 1998;53(11):715-8.
1998: André J Scheen
[How I study a patient with a low concentration of HDL cholesterol].
Revue médicale de Liège 1998;53(11):711-4.
1998: André J Scheen
[Pharma-clinics. Drug of the month. Premelle (conjugated estrogens + medroxyprogesterone].
Revue médicale de Liège 1998;53(10):638-40.
1998: Régis P Radermecker; André J Scheen; MR Letiexhe; Pierre J Lefèbvre; Patrick De Mol
[Viral implications in the etiopathogenesis of type 1 diabetes: current update].
Revue médicale de Liège 1998;53(10):597-602.
1998: André J Scheen; Pierre J Lefèbvre
[Lessons from the "United Kingdom Prospective Diabetes Study"].
Revue médicale de Liège 1998;53(9):576-8.
1998: Laurent Weekers; André J Scheen; J P Godon
[How I examine...diabetic nephropathy. Second part: assessment of glomerular filtration].
Revue médicale de Liège 1998;53(9):571-5.
1998: André J Scheen
[Therapeutic update 1997-1998].
Revue médicale de Liège 1998;53(9):518-23.
1998: Françoise Luyckx; André J Scheen; Claude Desaive; W Dewe; JE Gielen; Pierre J Lefebvre
Effects of gastroplasty on body weight and related biological abnormalities in morbid obesity.
Diabetes & metabolism 1998;24(4):355-61.
1998: André J Scheen
Clinical efficacy of acarbose in diabetes mellitus: a critical review of controlled trials.
Diabetes & metabolism 1998;24(4):311-20.
1998: André J Scheen
[Pharma-clinics. Doping with erythropoietin or the misuse of therapeutic advances].
Revue médicale de Liège 1998;53(8):499-502.
1998: Laurent Weekers; André J Scheen; Pierre J Lefebvre
[How I evaluate...diabetic nephropathy. First part: micro- and macroalbuminuria].
Revue médicale de Liège 1998;53(8):494-8.
1998: André J Scheen
[Therapeutic update 1997-1998 (1). First part].
Revue médicale de Liège 1998;53(8):459-66.
1998: André J Scheen
[Drug clinics. Drug of the month. Atorvastatin (Lipitor)].
Revue médicale de Liège 1998;53(6):374-7.
1998: André J Scheen; Pierre J Lefèbvre
[Pharmaco-economics of type 2 diabetes].
Revue médicale de Liège 1998;53(5):285-9.
1998: André J Scheen
[Pharmaco-economics of hypolipidemic agents: analysis of factors influencing the cost-effectiveness relation].
Revue médicale de Liège 1998;53(5):270-5.
1998: André J Scheen
[Drug clinics. The drug of the month. Alendronate (Fosamax)].
Revue médicale de Liège 1998;53(4):220-2.
1998: JC Philips; André J Scheen; E Firre; M Robin; P Cambier; Pierre J Lefèbvre
[Clinical case of the month. Galloping nephropathy in a patient with type 2 diabetes].
Revue médicale de Liège 1998;53(4):171-4.
1998: Françoise Luyckx; Claude Desaive; Albert Thiry; Walthère Dewé; André J Scheen; JE Gielen; Pierre J Lefèbvre
Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty.
International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity 1998;22(3):222-6.
1998: André J Scheen
[How I study hypertriglyceridemia].
Revue médicale de Liège 1998;53(2):103-5.
1998: André J Scheen
[How I treat a diabetes type 2 patient: the DREAM project for better general practitioner-specialist collaboration. Diabetes Reinforcement of Adequate Management].
Revue médicale de Liège 1998;53(2):58-62.
1998: André J Scheen; Pierre J Lefèbvre
Oral antidiabetic agents. A guide to selection.
Drugs 1998;55(2):225-36.
1998: André J Scheen
[Drug clinics. The drug of the month. Ranitidine bismuth citrate (Pylorid)].
Revue médicale de Liège 1998;53(1):41-4.
1998: André J Scheen
[Syndrome X, at the crossroads of metabolic and cardiovascular diseases].
Revue médicale de Liège 1998;53(1):29-32.
1998: André J Scheen
[Drug clinics. Clinical drug trials: the importance and role of the general practitioner].
Revue médicale de Liège 1998;53(1):17-20.
1997: Françoise Luyckx; André J Scheen
[Drug clinics. Drug of the month. Legalon (silymarin)].
Revue médicale de Liège 1997;52(12):792-6.
1997: André J Scheen
[The controversy apropos of the discovery of insulin. Its history seen from the aspect of philately].
Revue médicale de Liège 1997;52(12):756-9.
1997: André J Scheen
[Lamotrigine (Lamictal)].
Revue médicale de Liège 1997;52(11):738-40.
1997: Françoise Luyckx; André J Scheen; Jacques Gielen; Pierre J Lefèbvre
[The adrenergic beta-3 receptor: a role in the genetic predisposition to obesity and diabetes?].
Revue médicale de Liège 1997;52(11):703-8.
1997: André J Scheen
[Could homeopathy find its legitimacy in the "positive" results of a meta-analysis?].
Revue médicale de Liège 1997;52(11):694-7.
1997: M Pieron; André J Scheen; Jean-Louis Corhay; MF Radermecker; P J Lefebvre
[Bronchial reactivity in diabetic patients].
Revue des maladies respiratoires 1997;14(5):379-85.
1997: Françoise Luyckx; André J Scheen; Jacques Gielen; Pierre J Lefèbvre
[How I investigate...the insulin resistance syndrome using biological markers].
Revue médicale de Liège 1997;52(10):686-91.
1997: Françoise Luyckx; André J Scheen; Jacques Gielen; Pierre J Lefèbvre
[From leptin, a signal from the adipocyte to the brain, to the neurobiology of obesity].
Revue médicale de Liège 1997;52(10):644-8.
1997: André J Scheen
[Drug-clinics. The hue and cry over central appetite suppressants!].
Revue médicale de Liège 1997;52(9):613-5.
1997: André J Scheen
[Drug-clinics. The drug of the month. Imitrex nasal spray (sumatriptan)].
Revue médicale de Liège 1997;52(9):610-2.
1997: André J Scheen; Nicolas Paquot; Pierre J Lefèbvre
[How I investigate the new criteria for the diagnosis of diabetes mellitus].
Revue médicale de Liège 1997;52(9):606-9.
1997: André J Scheen
Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s. Achievements and future developments.
Drugs 1997;54(3):355-68.
1997: MR Letiexhe; André J Scheen; Pierre J Lefèbvre
Plasma leptin levels, insulin secretion, clearance and action on glucose metabolism in anorexia nervosa.
Eating and weight disorders : EWD 1997;2(2):79-86.
1997: André J Scheen
[The mechanism of action of hypolipidemic drugs].
Revue médicale de Liège 1997;52(6):445-6.
1997: André J Scheen
[Drug of the month. Fluvastatin (Lescol)].
Revue médicale de Liège 1997;52(6):442-4.
1997: André J Scheen
The medicine of the month. Losartan (Cozaar).
Revue médicale de Liège 1997;52(5):367-9.
1997: JC Philips; MR Letiexhe; Nicolas Paquot; André J Scheen; Pierre J Lefèbvre
[How I investigate... a patient newly diagnosed with/or at risk of diabetes type 1].
Revue médicale de Liège 1997;52(5):363-6.
1997: André J Scheen; M Marchand; J Juchmes
[Image of the month. Immediate vasovagal syncope].
Revue médicale de Liège 1997;52(5):315.
1997: André J Scheen
[Pharma-Clinics. The drug of the month. Meloxicam (Mobic)].
Revue médicale de Liège 1997;52(4):309-11.
1997: André J Scheen
[Particulars about pharmacotherapy in the elderly patient].
Revue médicale de Liège 1997;52(4):201-4.
1997: André J Scheen
[Pharma-clinics. How I treat... A patient with orthostatic hypotension].
Revue médicale de Liège 1997;52(3):134-7.
1997: André J Scheen; G de Fooz; M Marchand
[How I explore... a patient with orthostatic hypotension].
Revue médicale de Liège 1997;52(2):116-9.
1997: F Bustin; S R Pestieau; Nicolas Paquot; André J Scheen; Pierre J Lefèbvre
[Energy expenditure in man].
Revue médicale de Liège 1997;52(2):101-4.
1997: André J Scheen
[Pharmaco-economic aspects of hypolipidemic treatment].
Revue médicale de Liège 1997;52(1):16-21.